Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	29.34	-56.42	-55.19	872.13	-199.43	-278.02
Depreciation & Amortization	5.61	6.12	6.15	7.02	8.6	6.97
Loss (Gain) From Sale of Assets	0.2	0.03	1.35	-2.72	0.04	-
Asset Writedown & Restructuring Costs	-	4.51	-	-	-	-
Loss (Gain) From Sale of Investments	-2.3	-2.51	-1.9	-	-	-
Stock-Based Compensation	19.82	21.39	25.37	39.73	62.06	62.98
Other Operating Activities	-15.71	-5.03	5.56	-960.95	-67.5	-16.9
Change in Accounts Receivable	-1.42	-0.97	-0.69	-2.72	1.8	6.13
Change in Accounts Payable	0.76	0.75	0.01	-1.61	-3.53	3.66
Change in Unearned Revenue	-	-	-0.22	-0.19	-11.46	-26.47
Change in Income Taxes	5.82	9.91	1.1	63.95	-0.19	-8.54
Change in Other Net Operating Assets	201.58	10.67	-8.54	-17.08	-26.17	-12.56
Operating Cash Flow	243.7	-11.54	-27	-186.99	-207.86	-250.4
Capital Expenditures	-0.22	-0.33	-2.49	-0.57	-3.41	-6.62
Sale of Property, Plant & Equipment	-	-	1.51	4.58	0.01	0.06
Investment in Securities	-87.67	14.91	-31.72	54.87	127.89	17.27
Other Investing Activities	-2.29	-2.29	-	1,095	-	-
Investing Cash Flow	-90.19	12.28	-32.7	1,154	124.49	10.72
Long-Term Debt Issued	-	-	-	-	-	380
Long-Term Debt Repaid	-	-	-	-631.6	-10.73	-235.35
Net Debt Issued (Repaid)	-	-	-	-631.6	-10.73	144.65
Issuance of Common Stock	0.46	0.61	0.62	0.8	111.65	144.98
Repurchase of Common Stock	-2.58	-3.1	-199.55	-132.28	-9.06	-9.75
Other Financing Activities	-	-	-	4.28	-	-16.8
Financing Cash Flow	-2.12	-2.5	-198.93	-758.81	91.86	263.09
Net Cash Flow	151.4	-1.75	-258.63	208.21	8.5	23.4
Free Cash Flow	243.48	-11.87	-29.49	-187.56	-211.26	-257.02
Free Cash Flow Margin	303.11%	-18.43%	-51.35%	-365.29%	-381.96%	-357.68%
Free Cash Flow Per Share	4.82	-0.24	-0.53	-2.55	-3.04	-4.12
Cash Interest Paid	-	-	-	22.24	39.03	24.02
Cash Income Tax Paid	21.77	0.11	0.02	117.97	-4.09	0.01
Levered Free Cash Flow	10.48	-42	-12.22	24	-115.85	-170.49
Unlevered Free Cash Flow	12.06	-40.41	-10.75	27.98	-110.5	-165.15
Change in Working Capital	206.74	20.36	-8.34	42.35	-39.55	-37.78

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q